Figure 5

Non-opsonic phagocytosis is strain dependent and involves α-glucans on Mtb. (A) PMN were incubated with FITC labeled-Mtb opsonized (serum) with intact or heated (ø) PPD negative serum (10:1 Mtb:PMN). Results are expressed as% of PMN that phagocytosed Mtb (% PMN Mtb FITC ± SE); Ra vs. Ra + serum: *p < 0.05; M vs. M + serum: ***p < 0.001; Ra vs. M: ^φp < 0.05; R + serum vs. R + serum-ø: ^##p < 0.01; M + serum vs. M + serum-ø: ^##p < 0.01 (B) PMN were incubated with blocking anti-CD11b antibodies prior to incubation with FITC-Mtb opsonized or not. Results are expressed as% of PMN that phagocytosed Mtb (% PMN Mtb FITC ± SE); Ra vs. Ra + serum: *p < 0.05; M vs. M + serum: ***p < 0.001; Ra vs. Ra + aCD11b: ^#p < 0.05; Ra + serum vs. Ra + serum + aCD11b: ^##p < 0.05; M + serum vs. M + serum + aCD11b: ^##p < 0.05; Ra, Ra + aCD11b and Ra + serum + aCD11b vs. M, M + aCD11b and M + serum + aCD11b: ^φp < 0.02 (C) PMN were incubated with opsonized or non-opsonized FITC-Mtb that were treated (Mtb e) or not with α-glycosidase. Results are expressed as% of PMN that phagocytosed Mtb (% PMN Mtb FITC ± SE); Ra vs. Ra + serum: *p < 0.05; M vs. M + serum: ***p < 0.001; Ra vs. Ra e and M vs. M e: ^##p < 0.01; Ra, Ra + serum and Ra e + serum vs. M, M e and M e + serum: ^φp < 0.05.